SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Jaguar Uranium Corp.

(Name of Issuer)

Class A Common Shares, no par value

(Title of Class of Securities)

Graham du Preez
217 Queen Street West, Suite 401,
Toronto, A6, M5V 0R2
1-833-572-2333

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

02/12/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP Number(s):

Name of reporting person

IsoEnergy Ltd.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 253,150.00
8	Shared Voting Power 3,000,000.00
9	Sole Dispositive Power 253,150.00
10	Shared Dispositive Power 3,000,000.00

Aggregate amount beneficially owned by each reporting person

3,253,150.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

16.1 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP Number(s):

Name of reporting person

Consolidated Uranium Inc.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,000,000.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,000,000.00

Aggregate amount beneficially owned by each reporting person

3,000,000.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

14.9 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Class A Common Shares, no par value

(b)

Name of Issuer:

Jaguar Uranium Corp.

(c)

Address of Issuer's Principal Executive Offices:

3-1136 Centre Street, Thornhill, ONTARIO, CANADA , L4J 3M8.

Item 2.

Identity and Background

(a)

This Schedule 13D (this "Statement") is being filed by IsoEnergy Ltd. ("IsoEnergy") and Consolidated Uranium Inc. ("Consolidated Uranium"), a wholly owned subsidiary of IsoEnergy (together with IsoEnergy, the "Reporting Persons"). The additional information required by General Instruction C to Schedule 13D is attached hereto as Schedule A and is hereby incorporated by reference.

(b)

The address of the principal executive offices of each of the Reporting Persons is 217 Queen Street West, Suite 401, Toronto, Ontario, Canada M5V 0R2. The additional information required by General Instruction C to Schedule 13D is attached hereto as Schedule A and is hereby incorporated by reference.

(c)

IsoEnergy is an exploration-stage uranium mining company with properties in Canada, the United States and Australia. Consolidated Uranium is a wholly owned subsidiary of IsoEnergy. IsoEnergy's common shares trade on the Toronto Stock Exchange under the symbol ISO and on the NYSE American under the symbol ISOU. The additional information required by General Instruction C to Schedule 13D is attached hereto as Schedule A and is hereby incorporated by reference.

(d)

The Reporting Persons and the individuals listed on Schedule A hereto have not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)

The Reporting Persons and the individuals listed on Schedule A hereto have not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction, as a result of which proceeding any such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)

The information required by General Instruction C to Schedule 13D is attached hereto as Schedule A and is hereby incorporated by reference.

Item 3.

Source and Amount of Funds or Other Consideration

The information disclosed under Item 4 below is hereby incorporated by reference into this Item 3. 253,500 common shares ("Common Shares") of Jaguar Uranium Corp. (the "Company") were obtained by IsoEnergy through the Company's initial public offering for an aggregate purchase price of $1,014,000. 2,000,0000 Common Shares were obtained by Consolidated Uranium in connection with its initial investment in the Company in exchange for certain mining assets. The remaining 1,000,000 Common Shares beneficially owned by the Reporting Persons were issued as additional consideration pursuant to the contractual arrangements described herein.

Item 4.

Purpose of Transaction

The Reporting Persons acquired the Common Shares for investment purposes. The Reporting Persons intend to review their investment in the Company on a continuing basis and, depending upon various factors, including without limitation, any discussions between the Reporting Persons and representatives of the Company, the Company's financial position and strategic direction, overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of securities of the Company at prices that would make the purchase or sale of such securities desirable, the Reporting Persons may: (i) increase or decrease their position in the Company through, among other things, the purchase or sale of securities of the Company, including through transactions involving the Common Shares and/or other equity, debt, notes, other securities, or derivative or other instruments that are based upon or relate to the value of securities of the Company in the open market or otherwise; (ii) enter into transactions that increase or hedge their economic exposure to the Common Shares without affecting their beneficial ownership of the Common Shares; or (iii) consider or propose one or more of the actions described in subparagraphs (a) - (j) of Item 4 of Schedule 13D.

Item 5.

Interest in Securities of the Issuer

(a)

The aggregate number and percentage of the Common Shares that are beneficially owned by the Reporting Persons and as to which the Reporting Persons have sole voting power, shared voting power, sole dispositive power and shared dispositive power are set forth on the cover pages of this Statement, and such information is incorporated herein by reference. In addition, the persons in Schedule A have sole voting power, shared voting power, sole dispositive power and shared dispositive power over the number of shares described therein. The percentages used herein are calculated based on an aggregate of 20,193,777 Common Shares outstanding as of February 12, 2026 based on the information contained in the Company's prospectus dated February 11, 2026.

(b)

The information in Item 5(a) of this Statement is incorporated herein by reference.

(c)

Information concerning the Common Shares purchased by (or on behalf of) the Reporting Persons and any person listed on Schedule A during the 60-day period prior to this filing is set forth in Schedule B hereto and is incorporated herein by reference. Except as described in Schedule B, none of the Reporting Persons nor any person listed in Schedule A has effected any transactions in the Common Shares during such 60-day period.

(d)

No person other than the Reporting Persons is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares beneficially owned by the Reporting Persons.

(e)

Not applicable.

Item 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

IsoEnergy is party to an investor rights agreement, dated July 19, 2024, with the Company (the "IRA"). Pursuant to the IRA, IsoEnergy is entitled to participate in future equity financings, including the issuance of equity securities or securities convertible into or exercisable for equity securities in any public or private offering, on terms consistent with those offered to other investors, subject to certain exceptions. IsoEnergy is also entitled to nominate one individual to the Company's board of directors. The IRA will terminate if and when IsoEnergy's ownership percentage in the Company falls below 5%. The foregoing summary of the IRA is not intended to be complete and is qualified in its entirety by reference to the full text of the IRA, which is filed as Exhibit 1 hereto and is incorporated herein by reference. Consolidated Uranium is party to a share purchase agreement, dated July 17, 2024 with the Company (the "SPA"). Pursuant to the SPA, the Company acquired certain mining assets from Consolidated Uranium in consideration of the issuance of 2,000,000 Common Shares and the grant of certain net smelter returns royalties on certain mining assets as well as the right to receive additional shares in certain circumstances. The foregoing summary of the SPA is not intended to be complete and is qualified in its entirety by reference to the full text of the SPA, which is filed as Exhibit 2 hereto and is incorporated herein by reference.

Item 7.

Material to be Filed as Exhibits.

Exhibit 1: Investor Rights Agreement, dated July 19, 2024, by and between Jaguar Uranium Corp. and IsoEnergy Ltd. (incorporated by reference to Exhibit 10.5 to the Company's Form S-1/A, filed with the Commission on January 30, 2026). Exhibit 2: Share Purchase Agreement, dated July 17, 2024, by and between Jaguar Uranium Corp. and Consolidated Uranium Inc. (incorporated by reference to Exhibit 10.3 to the Company's Form S-1/A, filed with the Commission on January 30, 2026). Exhibit 3: Schedule A to Item 2 of this Statement. Exhibit 4: Schedule B to Item 5 of this Statement. Exhibit 5: Agreement relating to the filing of joint acquisition statements as required by Rule 13d-1(k)(1) under the Act.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

IsoEnergy Ltd.

Signature:	/s/ Graham du Preez
Name/Title:	Graham du Preez/Chief Financial Officer
Date:	03/03/2026

Consolidated Uranium Inc.

Signature:	/s/ Graham du Preez
Name/Title:	Graham du Preez/Chief Financial Officer
Date:	03/03/2026

SEC Form SCHEDULE 13D filed by Jaguar Uranium Corp.